|
Caveats
One thing that I think is particularly interesting about the TEACH trial is that it isn't limited to those who missed out on Herceptin long ago, but is available as an alternative in place of trastuzumab to those currently completing chemotherapy:
[must have] "received and completed a prior neoadjuvant or adjuvant chemotherapy regimen containing either an anthracycline or a taxane; or any cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimen"
However, the catch is that for those who decide to participate, some will end up receiving placebo and some will end up receiving the lapatinib/Tykerb. So doing the trial doesn't mean that a participant will have any more protection from recurrence than if they didn't, if they do end up on placebo.
AlaskaAngel
|